2024-11-05 - Analysis Report
## Pfizer Inc (PFE) Stock Analysis

**1. Performance vs. S&P 500:**

Pfizer Inc (PFE) is a multinational pharmaceutical corporation that develops and produces medicines and vaccines. The company has underperformed the S&P 500 significantly, with a cumulative return of -14.53% compared to the S&P 500's 131.28%. This represents a substantial gap of -145.81%, placing it in the 2.49th percentile of historical performance relative to the S&P 500.

**Alpha and Beta Analysis:**

The table reveals a fluctuating performance over the years, with PFE exhibiting both positive and negative alpha. 

* **High Alpha:** 2018 (26.8%), 2021 (31.6%) indicate strong outperformance compared to the market. 
* **Negative Alpha:** 2016 (-9.7%), 2017 (-8.9%), 2019 (-38.0%), 2020 (-16.0%), 2023 (-68.6%), 2024 (-27.3%) suggest underperformance.

Beta, generally ranging from 0.5 to 0.9, indicates PFE's relatively low volatility compared to the market, except for 2021 (0.0), where it was less volatile. 

**2. Recent Price Movement:**

* **Closing Price:** $27.76
* **5-day Moving Average:** $28.23
* **20-day Moving Average:** $28.91
* **60-day Moving Average:** $28.97

PFE's closing price is below all three moving averages, indicating a potential downtrend. 

**3. Technical Indicators:**

* **RSI:** 23.08 - PFE is currently in oversold territory, suggesting a potential rebound. 
* **PPO:** -0.42 -  The negative value indicates a bearish trend, but the recent increase in Delta_Previous_Relative_Divergence (0.17) suggests a potential short-term uptrend.
* **Expected Return:** 0.0% -  This indicates that PFE is expected to perform in line with the S&P 500 over the long term. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

Pfizer's most recent earnings report for Q3 2024 shows a beat on both EPS and Revenue. The company exceeded analysts' expectations, with an EPS of $1.06 compared to the estimated $0.614. 

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---|---|---|
| 2024-06-30 | $13.28B | $9.98B 75.16% |
| 2024-03-31 | $14.88B | $11.50B 77.29% |
| 2023-12-31 | $14.25B | $6.69B 46.92% |
| 2023-09-30 | $13.23B | $3.96B 29.95% |
| 2023-06-30 | $13.01B | $9.77B 75.11% |

**Capital and Profitability:**

| Quarter  | Equity    | ROE |
|---|---|---|
| 2024-06-30 | $87.70B  | 0.05% |
| 2024-03-31 | $92.28B  | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |
| 2023-06-30 | $99.02B | 2.35% |

Pfizer has shown strong revenue growth and profitability over the past quarters. The company's profit margin has been consistently high, indicating a healthy financial position. However, the ROE has been fluctuating, with a recent decline in the latter part of 2023. 

**6. News and Recent Issues:**

* **Recent Earnings Release:** Pfizer's recent earnings release, as mentioned above, showcased a beat on both EPS and revenue, demonstrating a positive outlook for the company's future performance.
* **Analyst Opinions and Performance Highlights:** Finbold reports that analysts are generally bullish on PFE, with a median price target of $41.27. This reflects an upside potential of over 48% from the current price. 

**7. Overall Analysis:**

Pfizer, despite its recent underperformance, remains a financially strong company with a consistent history of profitability and revenue growth. The company has a strong track record of innovation and its focus on high-growth areas like oncology and mRNA vaccines suggests potential future upside. The recent positive earnings report further strengthens this belief. 

However, investors should consider the long-term potential and be prepared for potential short-term volatility. PFE's underperformance against the S&P 500 requires careful consideration. Despite the current oversold conditions, the technical indicators suggest a mixed outlook. 

**8. Conclusion:**

Pfizer Inc is a company with a strong financial position and a history of innovation. While the stock has underperformed the market in the recent past, its recent positive earnings and bullish analyst sentiment suggest potential upside. However, investors should consider the stock's long-term potential and be prepared for potential short-term volatility. 

**Disclaimer:** This analysis is provided for informational purposes only and does not constitute financial advice. 
